JPRN-jRCT2080223418已完成1 期
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Single Oral Administration in Japanese Healthy Adult Male Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
o safety concern was noted in single oral administration of esaxerenone at a dose of 5 mg to 200 mg in Japanese healthy adult subjects.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •1)Japanese male
- •2)Persons >= 20 years and =< 45 years of age at the time of informed consent
- •3)Persons with a body mass index (BMI; calculated by body weight [kg]/height [m]2) of >= 18.5 kg/m2 and < 25.0 kg/m2 at the screening examination
排除标准
- •1)Persons with hypersensitivity or idiosyncratic reactions to a drug, (such as penicillin allergy)
- •2)Persons with drug or alcohol dependence
研究者
相似试验
已完成
1 期
A Phase 1 Study of CS-3150 Evaluation of Safety, Pharmacokinetics, and Pharmacodynamics after Multiple Oral Administration in Japanese Healthy Adult Male SubjectsHealthy volunteersJPRN-jRCT2080223421DAIICHI SANKYO Co.,Ltd.40
已完成
1 期
Clinical Pharmacology Study of CS-3150 A single dose study to assess the absolute bioavailability and effect of food on the pharmacokinetics of CS-3150 in Japanese healthy subjectsHealthy volunteersJPRN-jRCT2080223397DAIICHI SANKYO Co.,Ltd.24
已完成
1 期
Clinical Pharmacology Study of CS-3150 Evaluation of the effect of repeated dose of itraconazole orally administered to healthy Japanese adult male on the pharmacokinetics of CS-3150Healthy volunteersJPRN-jRCT2080223231DAIICHI SANKYO Co.,Ltd.20
已完成
3 期
A Study of CS-3150 to Evaluate Efficacy and Safety in Patients with Primary AldosteronismPrimary aldosteronismJPRN-jRCT2080223294DAIICHI SANKYO Co.,Ltd.44
已完成
3 期
A Study of CS-3150 to Evaluate Efficacy and Safety to in combination with ARB or ACE inhibitor in Hypertensive Patients with Moderate Kidney DysfunctioHypertension with moderate renal impairmentJPRN-jRCT2080223233DAIICHI SANKYO Co.,Ltd.58